All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development & Partnerships

Novartis, Argo Biopharma expand RNA partnership for cardiovascular medicines with $160M upfront payment
Licensing deal, cardiovascular, RNA medicines, milestone payments, global, R&D - Read more

Mytos partners with StemSight, Rinri Therapeutics, and Novadip to automate cell manufacturing for diverse therapeutic applications
Manufacturing agreement, cell therapy, automation, regenerative medicine, multiple therapeutic areas - Read more

LenioBio, AffinityAI partner to accelerate protein discovery by combining AI design with cell-free expression technology
Research collaboration, AI/ML, drug discovery, protein therapeutics, cell-free technology, high-throughput screening - Read more

PRESENTED BY PROMOVEO HEALTH
Contract Sales Reps = Fast Deployment + Lower Cost

We've built 100+ pharma sales teams for companies of all sizes, and we can help you.

We build agile field teams that scale based on your needs - all with fast deployment + lower cost than full-time reps.

See how flexible can work - click here to learn more.

✅ More Good News ✅

THE GOOD
Clinical Trials

Pfizer, Valneva's VLA15 Lyme disease vaccine shows strong Ph2 immune response after third annual booster
Vaccine, infectious disease, protein subunit vaccine, Lyme disease, preventative, annual booster - Read more

SpliSense's Ph2 trial shows SPL84 antisense therapy improves lung function in cystic fibrosis patients
Antisense oligonucleotide, genetic, cystic fibrosis, CFTR gene, mutation-specific therapy, inhaled delivery - Read more

THE GOOD
Fundraises

Treeline Biosciences raises $200M Series A extension, advancing oncology pipeline with first clinical candidates
Oncology, small molecule, clinical-stage, cancer, drug discovery - Read more

Camena Bioscience raises funding from Mercia Ventures for antibody engineering technology
Antibody engineering, platform technology, services, preclinical - Read more

Galvanize Therapeutics raises $100M Series C for pulsed electric field therapies in oncology and chronic lung disease
Oncology, chronic lung disease, medical technology, pulsed electric field therapy, platform technology, chronic bronchitis - Read more

Mineralys Therapeutics raises $250M public offering for hypertension drug development and pre-commercialization
Hypertension, clinical-stage, cardiovascular, chronic kidney disease, small molecule - Read more

LPOXY raises $28M Series A for pivotal trial of C. difficile infection prevention pill
Infectious disease, clinical-stage, preventative, C. difficile, novel mechanism - Read more

THE GOOD
Investments

Gilead breaks ground on Foster City manufacturing hub, part of $32B U.S. investment plan
Biologics, manufacturing, strategic, operational, investment - Read more

THE GOOD
Politics & Policy

Pfizer, Moderna, Novavax defend COVID vaccines after Trump questions data transparency amid CDC upheaval
mRNA vaccine, infectious disease, regulatory, strategic - Read more

THE GOOD
Regulatory

FDA grants Ori Biotech's IRO cell and gene therapy manufacturing platform advanced manufacturing technology designation
Cell and gene therapy, manufacturing technology, regulatory approval, operational, strategic - Read more

PRESENTED BY YOU?
Get the attention of 2200+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Business Development & Partnerships

Gilead's Kite Pharma terminates $2.3B cell therapy collaboration with Shoreline Biosciences for off-the-shelf therapies
Deal termination, cell therapy, oncology, off-the-shelf therapies, R&D - Read more

THE BAD
Clinical Trials

Amgen, Zai Lab's bemarituzumab shows weakened survival benefit in Ph3 gastric cancer trial targeting FGFR2b
Monoclonal antibody, cancer, gastric cancer, FGFR2b target, combination therapy, clinical trial setback - Read more

Wave Life Sciences Ph1 RNA editing drug WVE-006 meets protein target for alpha-1 antitrypsin deficiency despite mixed investor response
RNA therapy, metabolic disease, oligonucleotide, alpha-1 antitrypsin deficiency, RNA editing, genetic disorder - Read more

THE BAD
Politics & Policy

House Republicans propose 6% budget cut to HHS, with 19% CDC reduction and elimination of AHRQ
Government funding, healthcare policy, financial, operational, regulatory - Read more

ABPI calls for UK government to revamp life sciences investment evaluation amid AstraZeneca's US pivot
Manufacturing, policy, economic, strategic, investment - Read more

THE BAD
Regulatory

FDA's Prasad tightens COVID vaccine approvals, requiring larger studies and questioning benefits for healthy individuals
mRNA vaccine, infectious disease, regulatory, policy change - Read more

THE BAD
Strategic Plans

AstraZeneca surrenders Indian manufacturing license, accelerating planned exit from Bangalore facility by 2026
Operational, manufacturing, strategic, cost reduction - Read more

THE UGLY
Politics & Policy

HHS employees demand RFK Jr.'s resignation amid CDC leadership turmoil and staff safety concerns
Public health policy, political controversy, organizational, management crisis - Read more

RFK Jr. announces CDC reorganization, blames US COVID deaths on chronic disease in controversial WSJ op-ed
Public health policy, infectious disease, regulatory, operational, reform - Read more

Trump questions COVID vaccine efficacy as CDC director firing sparks staff exodus amid policy disputes
mRNA vaccine, infectious disease, regulatory, political - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here